SS-31 (Elamipretide)

What is SS-31 aka Elamipretide?

Overview

Also known as Forzinity, BioAmplify, MTP-131, Bendavia

It helps damaged mitochondria produce energy more efficiently while reducing harmful by-products of energy production. SS-31 is being studied in clinical trials for mitochondrial disorders and heart disease. A mitochondrial peptide, approved in 2025 for the rare genetic disease Barth syndrome.

The technical version

SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that binds to and stabilizes cardiolipin, a specialized lipid in the inner mitochondrial membrane that plays a key role in cellular energy production.

SS-31 aims to target one specific molecule that exists in your mitochondria called cardiolipin which is a fat that is where energy is produced. This fat is part of the inner wall of the mitochondria.

It concentrates inside mitochondria

SS-31 is a small, mitochondria-targeted peptide designed to accumulate in the inner mitochondrial membrane, where the cell’s energy-producing machinery is located. Unlike compounds that act broadly throughout the cell, SS-31 has chemical properties that help it target this specific area.

This targeted delivery is important because mitochondria generate ATP (adenosine triphosphate), the main energy currency used by cells. By acting close to the machinery responsible for energy production, SS-31 may help support mitochondrial function without needing to act equally throughout the entire cell.

Its mitochondrial targeting is a key part of its mechanism, although its effects and effective dose depend on the condition being treated. It should not be assumed that targeted delivery automatically makes a compound effective or safe at very low doses.

It binds to and stabilizes cardiolipin

Cardiolipin is a specialized fat, or lipid, found primarily in the inner mitochondrial membrane. It helps organize and support the protein complexes responsible for producing ATP.

When mitochondrial membranes and cardiolipin are disrupted, these protein complexes may function less efficiently. This can interfere with energy production and contribute to increased production of reactive oxygen species (ROS), chemically reactive molecules that can damage cellular components when present in excess.

SS-31 interacts with cardiolipin and helps stabilize its structure and local membrane environment. This may support the organization and function of the mitochondrial energy-producing machinery, improve the efficiency of energy production, and reduce excessive oxidative stress.

The important distinction is that SS-31 is not simply a conventional antioxidant that neutralises free radicals throughout the body. Its proposed action is more targeted: it interacts with the mitochondrial membrane environment to help preserve the function of the machinery that produces cellular energy.

It was approved for a rare genetic disease

In September 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to elamipretide, marketed as Forzinity, to improve muscle strength in adults and children weighing at least 30 kg (approximately 66 lb) who have Barth syndrome. It became the first FDA-approved treatment for this rare genetic condition

Barth syndrome is an inherited disorder that affects mitochondrial function. It is associated with abnormalities in cardiolipin, which can impair the mitochondria’s ability to produce energy effectively. People with the condition may experience muscle weakness, fatigue, reduced exercise tolerance and serious heart problems.

The approval is significant because it represents a move from experimental mitochondrial research to an approved treatment for a specific disease. However, the approval was granted under the FDA’s accelerated approval pathway, based on improvements in knee-extensor muscle strength. Further research is required to confirm the clinical benefits.

What this means for anti-aging research

Although SS-31 has attracted interest for its potential to support mitochondrial function, its approval for Barth syndrome does not establish that it can slow aging, extend lifespan or reverse age-related mitochondrial decline in otherwise healthy people.

These are separate questions that require dedicated clinical studies. Results from rare-disease research, laboratory experiments or animal studies cannot automatically be applied to healthy people seeking longevity benefits.

At present, Forzinity’s FDA-approved indication is specifically for improving muscle strength in eligible patients with Barth syndrome. Broader uses, including general anti-aging, remain investigational rather than established medical applications.

The bigger picture

SS-31 is scientifically interesting because it targets a fundamental part of cellular energy production rather than simply addressing one downstream symptom.

• Targeting: It accumulates at the inner mitochondrial membrane.
• Stabilisation: It binds cardiolipin, helping support mitochondrial membrane structure and function.
• Clinical evidence: It has an FDA-approved use for Barth syndrome, while its potential applications in other conditions require further evaluation.

The central question is no longer just whether SS-31 can influence mitochondrial function. It is which patients benefit, how meaningful those benefits are, and whether the effects translate into better long-term health.